Assessment of hepatic fibrosis in hemodialysis children and adolescents by fibroscan and hyaluronic acid.

Background: Patients undergoing hemodialysis (HD) are more likely than the general population to contract the hepatitis C virus (HCV). Due to the possibility of developing cardiovascular disease and liver fibrosis, HCV hemodialysis patients' survival rates are lower than those without HCV. Evaluation of hepatic fibrosis by biochemical indicators such as serum hyaluronic acid and the evaluation of liver stiffness fibroscan can be used to evaluate the severity of fibrosis. Aim: To evaluate the role of fibro scan and hyaluronic acid (HA) for the detection of hepatic fibrosis in HD individuals who have HCV. Patients and methods: This cross-sectional study on HD children receiving regular hemodialysis was conducted in the Pediatric Nephrology Unit, Pediatrics Intensive Care Unit of Children Hospital, and Clinical Pathology Lab, Faculty of Medicine, Zagazig University. 54 patients were split into: Group 1: Hepatitis C individuals with HD make-up and Group 2: HD patients without hepatitis C. Serum hyaluronic acid and fibroscan were done. Results: Regarding serum hyaluronic acid, there is no statistically significant difference between the HD patient groups that were HCV positive and those that were HCV negative. There is a statistically significant correlation between serum hyaluronic acid and the degree of liver fibrosis, when performing a PAIRWISE comparison, F2 and F0 show a considerable difference. Conclusion: Fibroscan is a good noninvasive assessment of liver fibrosis in HD patients with HCV. Despite the study's small sa mple size, serum hyaluronic acid and the degree of liver fibrosis determined by fibroscan are significantly correlated. [ABSTRACT FROM AUTHOR]